netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.06  Expand sub section  Treatment of glaucoma
11.06  Expand sub section  Beta-blockers
11.06  Expand sub section  Prostaglandin analogues
11.06  Expand sub section  Sympathomimetics
11.06  Expand sub section  Carbonic anhydrase inhibitors and systemic drugs to top
Acetazolamide
(Ophthalmology)
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Adjunctive therapy for Open Angle Glaucoma And Ocular Hypertension

Provider notes

  • NMUH:
    • See link below
    • Immedidate release and modified release formulations are both available
  • RFL:
    • Immediate release only
  • RNOH: 
    • Immediate release only
  • UCLH:
  • WH:
    • As per NCL glaucoma guideline
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Brinzolamide 0.1% eye drops
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Approved for open-angle glaucoma and ocular hypertension (2nd line; after travoprost)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Use in line with NCL guideline below
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Brinzolamide 1% + Timolol 0.5% eye drops
(Azarga)
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Approved for open-angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Dorzolamide 2% + Timolol 0.5% eye drops
(Cosopt)
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Approved for ppen-angle glaucoma and ocular hypertension
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Dorzolamide 2% + Timolol 0.5% eye drops - unit dose
(Cosopt)
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for open-angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted to Ophthalmology 
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Dorzolamide 2% eye drops
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • Approved for open-angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Not to be used as first-line treatment - see link below
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
Dorzolamide 2% eye drops - unit dose
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Restricted to patients with true preservative allergy and/or evidence of epithelial toxicity from preservatives and/or severe dry eyes. See NCL guideline for place in therapy.

Provider notes

  • NMUH:
    • See NCL Glaucoma guideline
  • RFL:
    • Approved for open-angle glaucoma and ocular hypertension
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NCL JFC: Glaucoma Prescribing Guidelines
11.06  Expand sub section  Miotics
 ....
 Non Formulary Items
Brinzolamide 1% + Brimonidine 0.2% eye drops
(Simbrinza)
(Ophthalmic)

View adult BNF View SPC online View childrens BNF
Non Formulary

Combination therapies to be used when compliance / cost issues arise. See NCL guideline for place in therapy.

Link  NCL JFC: Glaucoma Prescribing Guidelines
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Homecare
Homecare

Traffic Light Status Information

Status Description

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary